ArticleFrontiers in oncology2024
Preliminary experience using MR-guided adaptive radiotherapy in head and neck cancer.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Visualization-driven digital technologies in oncology: current applications, technological advances, and future directions.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This retrospective study evaluates the dosimetric benefits of adaptive radiotherapy for head and neck cancer patients. Five patients with node-positive oropharyngeal squamous cell carcinoma were treated with MR-guided radiotherapy using the Elekta Unity MR-Linac, undergoing 3-4 offline adaptive plan modifications during their treatment. This study compared the dose delivered to organs at risk (OARs) in a full offline adaptive approach versus an approach accounting only for daily setup. Results demonstrated a reduction in mean dose to critical structures in the offline adaptive arm. For example, the pharynx avoidance structure showed mean dose reductions ranging from 1.4 Gy to 3.6 Gy, and the left parotid gland exhibited reductions from 1.5 Gy to 1.9 Gy. Overall, offline adaptive radiotherapy reduced the mean cumulative dose to OARs in 19 of the 23 evaluated structures. Despite some instances of higher doses, the offline adaptive approach generally resulted in lower cumulative doses, emphasizing its potential to mitigate radiation-induced side effects. These findings suggest that offline adaptive radiotherapy has the potential to enhance treatment efficacy by better accommodating anatomical changes during therapy, thereby improving patient outcomes and reducing treatment-related morbidity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.